NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, announced that it will present at the PODD 2025 Conference on Monday, Oct. 27, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston. President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company’s antiviral drug pipeline and platform technologies available for licensing.
The presentation comes as NanoViricides’ lead candidate, NV-387, advances toward Phase II clinical trials for MPox and respiratory viral infections. Preclinical studies have demonstrated strong efficacy against respiratory syncytial virus (RSV), Influenza A, and Coronaviruses, positioning NV-387 as a potential broad-spectrum treatment. The company is also developing NV-HHV-1 for the treatment of Shingles and has a pipeline targeting numerous viral diseases, including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.
NanoViricides’ platform technology is based on the TheraCour nanomedicine technology, licensed exclusively from TheraCour Pharma, Inc. The company holds worldwide exclusive perpetual licenses for several drugs with specific targeting mechanisms against a range of human viral diseases. The company’s business model involves licensing technology for specific application verticals, a strategy established at its foundation in 2005.
Investors can access the full press release at https://ibn.fm/Z4d0g and find the latest news and updates about NNVC at https://ibn.fm/NNVC.
The company acknowledges the lengthy and capital-intensive nature of drug development and notes that there is no assurance that any of its pharmaceutical candidates will demonstrate sufficient effectiveness and safety for human clinical development. However, the presentation at PODD 2025 underscores NanoViricides’ commitment to advancing its antiviral pipeline and exploring licensing opportunities for its platform technologies.
